Related Experiment Video

Updated: May 25, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by

You-Sub Won1, Seong-Wook Lee

  • 1Department of Molecular Biology, Institute of Nanosensor and Biotechnology, Dankook University, Yongin 448-701, Republic of Korea.

Journal of Biotechnology
|January 31, 2012
PubMed

Insights

A novel trans-splicing ribozyme targets the cancer-promoting AIMP2-DX2 RNA variant. This approach selectively replaces the aberrant RNA, offering a promising new strategy for lung cancer therapy.

Area of Science:

  • Molecular Biology
  • Cancer Genetics
  • RNA Therapeutics

Background:

  • AIMP2/p38 is a crucial scaffolding protein involved in tRNA synthetase complex assembly.
  • AIMP2 possesses anti-proliferative and pro-apoptotic functions.
  • A splicing variant, AIMP2-DX2, lacks exon 2, promotes lung tumorigenesis, and compromises normal AIMP2 tumor suppressor activity.

Purpose of the Study:

  • To develop a novel RNA-based cancer therapy targeting the AIMP2-DX2 splicing variant.
  • To investigate the efficacy of a trans-splicing ribozyme for selective RNA replacement in lung cancer cells.

Main Methods:

  • Development of a specific trans-splicing ribozyme designed to target AIMP2-DX2 RNA.
  • Utilizing high-fidelity trans-splicing reactions for RNA replacement within cancer cells.
  • Delivery of a suicide gene via the ribozyme to induce cancer cell death.

Main Results:

  • The developed ribozyme selectively targeted and replaced AIMP2-DX2 RNA, not normal AIMP2 RNA.
  • The ribozyme effectively delivered a suicide gene into AIMP2-DX2-expressing lung cancer cells.
  • Cancer cell growth was specifically and effectively retarded through prodrug treatment.

Conclusions:

  • AIMP2-DX2 RNA-targeting trans-splicing ribozyme represents a novel therapeutic strategy for lung cancer.
  • This RNA replacement approach offers selective targeting and effective cancer growth inhibition.
  • The developed ribozyme holds potential as a genetic agent for efficient lung cancer therapy.

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Using the E1A Minigene Tool to Study mRNA Splicing Changes10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...